MediciNova, Inc. (NASDAQ:MNOV) has been given an average broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.
Brokers have set a 1-year consensus target price of $19.67 for the company and are forecasting that the company will post ($0.11) EPS for the current quarter, according to Zacks. Zacks has also given MediciNova an industry rank of 90 out of 255 based on the ratings given to related companies.
Separately, BidaskClub cut shares of MediciNova from a “buy” rating to a “hold” rating in a research report on Saturday, October 13th.
Shares of NASDAQ MNOV opened at $10.78 on Tuesday. MediciNova has a 52 week low of $5.81 and a 52 week high of $14.50.
MediciNova (NASDAQ:MNOV) last issued its earnings results on Monday, July 23rd. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.04. As a group, sell-side analysts forecast that MediciNova will post -0.44 EPS for the current fiscal year.
MediciNova, Inc, a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company's product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders consisting of primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction.
Further Reading: What is the NASDAQ Stock Market?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.